GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arovella Therapeutics ALA.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.05

0.00%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Arovella Therapeutics — daily ASX:ALA

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Arovella Therapeutics on TradingView ↗
Market value
A$60.1m
Last close × shares
Volume
355.2k
Shares, 9 Nov 2026

About Arovella Therapeutics

Its shares trade on ASX under the ticker ALA.AX. It has been listed since 24 January 2002. In the fiscal year to 30 June 2025, it reported revenue of A$525,500 and a net loss of A$7.5m. At that date it held total assets of A$21.6m and shareholders' equity of A$20.1m.

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The firm is focused on developing therapies to treat human disease. The firm focuses two focus areas are oncology and conditions that impact the central nervous system. The Company’s technology includes iNKT Cell Therapy, DKK1-CAR-iNKT, AR19-iNKT + CF33-CD19, Anagrelide and ZolpiMist. The Company’s invariant natural killer T (iNKT) cell therapy pipeline through the license to the DKK1 monoclonal antibody (mAb). The company develops the DKK1 mAb as a chimeric antigen receptor to use in combination with its iNKT cell therapy platform. The firm is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. Anagrelide is for the treatment of metastatic disease granted in the United States, Europe, Japan and Australia. ZolpiMist is an oral spray of zolpidem tartrate to treat short- term insomnia.

Figures and description from our data supplier, not checked against the company's own report.

More about Arovella Therapeutics →

Latest on Arovella Therapeutics

Our reporting

We have not reported on Arovella Therapeutics yet.

Next results

25 Feb 2027

Due on 25 Feb 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Arovella Therapeutics's ticker?

Arovella Therapeutics trades as ALA.AX on ASX, under ISIN AU0000182784.

What was Arovella Therapeutics's last closing price?

0.05 on 9 Nov 2026. The figure is in AUD and is never converted.

When does Arovella Therapeutics next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.